Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Arcutis Biotherapeutics Inc's Business Segments
Arcutis Biotherapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 105
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 105 | 100% |
Revenue by Product & Service Category - Q1 FY2026
- ZORYVE foam47.1%
- ZORYVE cream 0.3%31%
- ZORYVE cream 0.15%20.6%
- ZORYVE cream 0.05%1.3%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| ZORYVE foam | $ 50 | 47.1% |
| ZORYVE cream 0.3% | $ 33 | 31% |
| ZORYVE cream 0.15% | $ 22 | 20.6% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
1 more categories available
Sign in to unlock the full Arcutis Biotherapeutics Inc dataset.
Description of Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics Inc is a pharmaceutical company focused on developing and commercializing innovative immunology and dermatology therapies to treat immune-mediated dermatological diseases, including psoriasis, atopic dermatitis, and seborrheic dermatitis. The company was founded in 2016 and is headquartered in Westlake Village, California.
Arcutis Biotherapeutics' pipeline includes several dermatology drug candidates, including ARQ-252, a topical treatment for chronic hand eczema that is currently in Phase 3 clinical trials; ARQ-154, a topical cream for the treatment of seborrheic dermatitis that has completed Phase 2 clinical trials and is expected to enter Phase 3 trials; and ARQ-171, a topical foam formulation currently in Phase 2 clinical trials for the treatment of atopic dermatitis.
The company's lead product candidate is ARQ-151, a topical cream for the treatment of plaque psoriasis. ARQ-151 received FDA approval in December 2020 and became available on the market in February 202
Beyond its dermatology pipeline, Arcutis Biotherapeutics is developing ARQ-531, a small-molecule inhibitor for the treatment of B-cell malignancies and other blood cancers. ARQ-531 is currently in Phase 1 clinical trials.
Arcutis Biotherapeutics has partnered with several leading pharmaceutical companies, including LEO Pharma and SQ Innovation, to advance its pipeline and bolster its research and development efforts. The company's goal is to provide innovative and effective treatments for patients suffering from dermatological diseases, and to become a leading player in the dermatology and immunology markets.
Arcutis Biotherapeutics' pipeline includes several dermatology drug candidates, including ARQ-252, a topical treatment for chronic hand eczema that is currently in Phase 3 clinical trials; ARQ-154, a topical cream for the treatment of seborrheic dermatitis that has completed Phase 2 clinical trials and is expected to enter Phase 3 trials; and ARQ-171, a topical foam formulation currently in Phase 2 clinical trials for the treatment of atopic dermatitis.
The company's lead product candidate is ARQ-151, a topical cream for the treatment of plaque psoriasis. ARQ-151 received FDA approval in December 2020 and became available on the market in February 202
Beyond its dermatology pipeline, Arcutis Biotherapeutics is developing ARQ-531, a small-molecule inhibitor for the treatment of B-cell malignancies and other blood cancers. ARQ-531 is currently in Phase 1 clinical trials.
Arcutis Biotherapeutics has partnered with several leading pharmaceutical companies, including LEO Pharma and SQ Innovation, to advance its pipeline and bolster its research and development efforts. The company's goal is to provide innovative and effective treatments for patients suffering from dermatological diseases, and to become a leading player in the dermatology and immunology markets.
Arcutis Biotherapeutics Inc. is a biopharmaceutical company specializing in the development of innovative therapies focused on dermatological conditions. The company is dedicated to addressing unmet medical needs across a spectrum of skin diseases, aiming to improve the quality of life for patients of all ages with these conditions. Below is a comprehensive overview of the segments, products, and services that Arcutis offers:
Segments
1. Psoriasis:
- Arcutis actively develops a variety of treatments targeted specifically at psoriasis, a chronic autoimmune condition characterized by skin redness, inflammation, and the formation of silvery scales. The company’s product line includes both topical and systemic therapies aimed at reducing the frequency and severity of flare-ups. These products are designed to not only alleviate symptoms but also to address the root causes of the disease at the immunologic level.
2. Atopic Dermatitis:
- Recognizing the challenges posed by atopic dermatitis, Arcutis offers advanced treatments that focus on calming inflammation and reliving severe itching. Their formulations target the immune dysregulation associated with atopic dermatitis, providing both short-term relief for acute symptoms and long-term management solutions for chronic cases. By enhancing the skin barrier and reducing inflammation, their treatments aim to improve patient outcomes significantly.
3. Seborrheic Dermatitis:
- The company also developed treatments aimed at managing seborrheic dermatitis, which manifests as flaky, itchy skin, often on the scalp and face. Arcutis offers products formulated to reduce sebum production and inflammation, thus alleviating symptoms and preventing recurrences. Their therapies are tailored to meet the unique needs of patients suffering from this condition, contributing to better skin health and comfort.
Products
1. Topical Treatments:
- Arcutis provides a broad range of topical formulations, including creams, ointments, gels, and solutions specifically designed for dermatological conditions. Their topical treatments are characterized by advanced formulations that enhance skin absorption and efficacy while minimizing side effects. These products often feature innovative delivery mechanisms to ensure targeted action and optimal therapeutic effects.
2. Oral Treatments:
- In addition to topical therapies, Arcutis has developed oral medications, including tablets and capsules, aimed at systemic treatment of dermatological diseases. These oral solutions work to manage more widespread symptoms of conditions such as psoriasis and atopic dermatitis by addressing inflammation and immune responses from within the body.
Services
1. Clinical Research:
- Arcutis is heavily invested in clinical research, conducting rigorous studies to evaluate the efficacy and safety of its products. Their clinical trials are comprehensive, evaluating various populations and disease severities, to gain a thorough understanding of their treatments impact. These studies are pivotal in bringing innovative therapies to market and ensuring that they meet the highest standards of care.
2. Medical Affairs:
- The Medical Affairs division at Arcutis plays a crucial role in disseminating knowledge about their products to healthcare professionals. This department offers educational resources, conducting outreach and engagement initiatives to support clinicians in understanding the clinical benefits of Arcutis’s treatments. Their aim is to empower healthcare providers with the necessary information to better serve their patients.
Conclusion
Arcutis Biotherapeutics Inc. is committed to advancing dermatological care through targeted therapies that address the complex nature of skin diseases. Their focus on psoriasis, atopic dermatitis, and seborrheic dermatitis underscores a dedication to improving patient outcomes. With a robust portfolio of topical and oral treatments, along with a strong emphasis on clinical research and medical education, Arcutis positions itself as a leader in the biopharmaceutical industry, keenly aware of the multifaceted needs of individuals suffering from dermatological conditions. The company’s ongoing innovations and research initiatives serve to enhance the quality of care available to these patients, reflecting Arcutiss commitment to transforming lives through effective treatment solutions.
Segments
1. Psoriasis:
- Arcutis actively develops a variety of treatments targeted specifically at psoriasis, a chronic autoimmune condition characterized by skin redness, inflammation, and the formation of silvery scales. The company’s product line includes both topical and systemic therapies aimed at reducing the frequency and severity of flare-ups. These products are designed to not only alleviate symptoms but also to address the root causes of the disease at the immunologic level.
2. Atopic Dermatitis:
- Recognizing the challenges posed by atopic dermatitis, Arcutis offers advanced treatments that focus on calming inflammation and reliving severe itching. Their formulations target the immune dysregulation associated with atopic dermatitis, providing both short-term relief for acute symptoms and long-term management solutions for chronic cases. By enhancing the skin barrier and reducing inflammation, their treatments aim to improve patient outcomes significantly.
3. Seborrheic Dermatitis:
- The company also developed treatments aimed at managing seborrheic dermatitis, which manifests as flaky, itchy skin, often on the scalp and face. Arcutis offers products formulated to reduce sebum production and inflammation, thus alleviating symptoms and preventing recurrences. Their therapies are tailored to meet the unique needs of patients suffering from this condition, contributing to better skin health and comfort.
Products
1. Topical Treatments:
- Arcutis provides a broad range of topical formulations, including creams, ointments, gels, and solutions specifically designed for dermatological conditions. Their topical treatments are characterized by advanced formulations that enhance skin absorption and efficacy while minimizing side effects. These products often feature innovative delivery mechanisms to ensure targeted action and optimal therapeutic effects.
2. Oral Treatments:
- In addition to topical therapies, Arcutis has developed oral medications, including tablets and capsules, aimed at systemic treatment of dermatological diseases. These oral solutions work to manage more widespread symptoms of conditions such as psoriasis and atopic dermatitis by addressing inflammation and immune responses from within the body.
Services
1. Clinical Research:
- Arcutis is heavily invested in clinical research, conducting rigorous studies to evaluate the efficacy and safety of its products. Their clinical trials are comprehensive, evaluating various populations and disease severities, to gain a thorough understanding of their treatments impact. These studies are pivotal in bringing innovative therapies to market and ensuring that they meet the highest standards of care.
2. Medical Affairs:
- The Medical Affairs division at Arcutis plays a crucial role in disseminating knowledge about their products to healthcare professionals. This department offers educational resources, conducting outreach and engagement initiatives to support clinicians in understanding the clinical benefits of Arcutis’s treatments. Their aim is to empower healthcare providers with the necessary information to better serve their patients.
Conclusion
Arcutis Biotherapeutics Inc. is committed to advancing dermatological care through targeted therapies that address the complex nature of skin diseases. Their focus on psoriasis, atopic dermatitis, and seborrheic dermatitis underscores a dedication to improving patient outcomes. With a robust portfolio of topical and oral treatments, along with a strong emphasis on clinical research and medical education, Arcutis positions itself as a leader in the biopharmaceutical industry, keenly aware of the multifaceted needs of individuals suffering from dermatological conditions. The company’s ongoing innovations and research initiatives serve to enhance the quality of care available to these patients, reflecting Arcutiss commitment to transforming lives through effective treatment solutions.